New Key Statistics Module, Z-Score and F-Score
NAS:SPRY Key Ratios
| Market Cap $ M | 1,485.15 |
| Enterprise Value $ M | 1,257.74 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 6.86 |
| Price/Sales | 3,045.80 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -0.47 |
| Beneish M-Score | -2.42 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -22.17 |
| EV-to-EBITDA | -23.66 |
| PEG | -- |
| Shares Outstanding M | 96.94 |
| Net Margin (%) | -8,968.40 |
| Operating Margin % | -11,347.20 |
| Pre-tax Margin (%) | -8,968.40 |
| Quick Ratio | 32.82 |
| Current Ratio | 32.82 |
| ROA % (ttm) | -18.84 |
| ROE % (ttm) | -19.40 |
| ROIC % (ttm) | -1,365.03 |
| Dividend Yield % | -- |
| Altman Z-Score | 131.24 |
SPRY Number of Guru Trades
SPRY Volume of Guru Trades
Gurus Latest Trades with NAS:SPRY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:SPRY is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
ARS Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:SPRY
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers